CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma
- 8 February 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Abdominal Radiology
- Vol. 42 (6), 1695-1704
- https://doi.org/10.1007/s00261-017-1072-0
Abstract
Purpose To develop a CT-based radiomics signature and assess its ability for preoperatively predicting the early recurrence (≤1 year) of hepatocellular carcinoma (HCC). Methods A total of 215 HCC patients who underwent partial hepatectomy were enrolled in this retrospective study, and all the patients were followed up at least within 1 year. Radiomics features were extracted from arterial- and portal venous-phase CT images, and a radiomics signature was built by the least absolute shrinkage and selection operator (LASSO) logistic regression model. Preoperative clinical factors associated with early recurrence were evaluated. A radiomics signature, a clinical model, and a combined model were built, and the area under the curve (AUC) of operating characteristics (ROC) was used to explore their performance to discriminate early recurrence. Results Twenty-one radiomics features were chosen from 300 candidate features to build a radiomics signature that was significantly associated with early recurrence (P < 0.001), and they presented good performance in the discrimination of early recurrence alone with an AUC of 0.817 (95% CI: 0.758–0.866), sensitivity of 0.794, and specificity of 0.699. The AUCs of the clinical and combined models were 0.781 (95% CI: 0.719–0.834) and 0.836 (95% CI: 0.779–0.883), respectively, with the sensitivity being 0.784 and 0.824, and the specificity being 0.619 and 0.708, respectively. Adding a radiomics signature into conventional clinical variables can significantly improve the accuracy of the preoperative model in predicting early recurrence (P = 0.01). Conclusions The radiomics signature was a significant predictor for early recurrence in HCC. Incorporating radiomics signature into conventional clinical factors performed better for preoperative estimation of early recurrence than with clinical variables alone.Keywords
Funding Information
- National Natural Science Foundation of China (81271569, 81271654, U1301258)
This publication has 41 references indexed in Scilit:
- Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular CarcinomaGastroenterology, 2016
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- Treatment of hepatocellular carcinoma: beyond international guidelinesLiver International, 2016
- A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral CentersAnnals of Surgery, 2013
- Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) stagingZeitschrift für Krebsforschung und Klinische Onkologie, 2012
- Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference reportThe Lancet Oncology, 2011
- Comparison of Surgical Resection and Transarterial Chemoembolization for Hepatocellular Carcinoma beyond the Milan Criteria: A Propensity Score AnalysisAnnals of Surgical Oncology, 2011
- Hepatectomy for Stage B and Stage C Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer ClassificationArchives of Surgery, 2008
- Longterm prognosis after hepatic resection for small hepatocellular carcinomaJournal of the American College of Surgeons, 2004
- Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver FunctionAnnals of Surgery, 2002